Importantly, the oncogenic properties of Notch3 have been further confirmed in studies demonstrating that a truncated, dominant negative form of Notch3 reduces tumor growth of t(15;19) NSCLC cell lines and that elevated expression of Notch3 occurs in 30–40% of primary lung tumors [11]. This evidence concerns the gene NOTCH3 and non-small cell lung carcinoma.